# Lupin receives USFDA approval for Cephalexin Oral Suspension

| BSE: 500257 | NSE: LUPIN | REUTERS: LUPN.BO | BLOOMBERG: LPC IN |
|---|---|---|---|

*Mumbai, August 18, 2005:* Lupin Ltd today announced that it has received USFDA approval for its Abbreviated New Drug Application (ANDA) for Cephalexin for Oral Suspension USP, 125 mg/5 ml and 250 mg/5 ml.

Lupin's Chairman Dr. Desh Bandhu Gupta said, "We have identified cephalosporins as one of our focus areas for the US market. The approval for Cephalexin, will further boost our product basket. Given our leadership position in Cephalexin, we believe we will be able to drive value in the marketplace through forward-integration into the finished product."

This is Lupin's sixth ANDA approved by the USFDA. Earlier it had received approvals for Ceftriaxone for injection, Cefotaxime for injection, Cefuroxime Axetil tablets and Cefixime tablets and oral suspension.

A main stay cephalosporin antibiotic, Cephalexin is indicated for the treatment of Respiratory tract infections caused by S. pneumoniae and S. pyogenes, skin and skin structure infections caused by staphylococci and/or streptococci, bone infections caused by staphylococci and/or P. mirabilis and genitourinary tract infections, including acute prostatitis, caused by E. coli, P. mirabilis, and K. pneumoniae.

## About Lupin

Headquartered in Mumbai, Lupin (http:/www.lupinworld.com) develops, manufactures and markets generic intermediates, active pharmaceutical ingredients and finished dosages. Its FY 2004-05 revenues were Rs.12 billion. 11 of Lupin's plant have been approved by the USFDA and two facilities have been approved by the UKMHRA

For further information contact:
**Raju Kane**
**The Source**
**Mobile: +91 98200 45656**
E-mail: **mail@sourcepr.com**